TheraRadar

Pharma Intelligence, Simplified

Landscape → Immunology

IBD

141 clinical trials

50 active
/
141 total (since 2015)
15
Phase 1 Active
47 total
26
Phase 2 Active
58 total
8
Phase 3 Active
20 total
9
Phase 4 Active
32 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) 2 1 0
Eli Lilly 1 0 0
Spyre Therapeutics, Inc. 1 0 0
Disc Medicine, Inc 1 0 0
Parvus Therapeutics, Inc. 1 0 0
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company 1 0 0
Mirador Therapeutics, Inc. 1 0 0
Resilience 1 0 0
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 1 0 0
Nanjing Immunophage Biotech Co., Ltd 1 0 0
Lmito Therapeutics Inc. 1 0 0
AstraZeneca 0 0 3
Bristol-Myers Squibb 0 2 1
NCT04844606 RECRUITING
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Eli Lilly and Company n=150
NCT03843385 RECRUITING
Transfer of FRozen Encapsulated Multidonor Stool Filtrate for Active Ulcerative COlitis
Andreas Stallmach n=129
NCT06274554 RECRUITING
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
Weill Medical College of Cornell University n=120
NCT07047339 RECRUITING
Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis
Changhai Hospital n=120
NCT07043036 NOT YET RECRUITING
Randomized Controlled Trial Comparing Remote Patient Monitoring vs Standard Care in IBD Patients Initiating or Changing Advanced Therapy
Resilience n=116
NCT05753267 RECRUITING
Fenofibrate in Ulcerative Colitis
Tanta University n=60
NCT05986136 RECRUITING
Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease
Mostafa Bahaa n=50
NCT06604273 RECRUITING
Unravelling Intestinal Fibrosis in Ulcerative Colitis
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=10
NCT05988528 COMPLETED
Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis
Mostafa Bahaa n=50
NCT02407236 COMPLETED
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development, LLC n=961
NCT04991324 COMPLETED
Cholecalciferol Comedication in IBD - the 5C-study
University Hospital, Basel, Switzerland n=150
NCT04060303 COMPLETED
ENhanced Recovery in CHildren Undergoing Surgery
Northwestern University n=599
NCT05726097 COMPLETED
Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure
Region Skane n=147
NCT03759288 TERMINATED
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
AstraZeneca n=89
NCT03961815 TERMINATED
Open-label Extension Study of Brazikumab in Crohn's Disease
AstraZeneca n=18
NCT04083157 COMPLETED
Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients
The University of Hong Kong n=104
NCT02680756 COMPLETED
Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD
Shield Therapeutics n=250
NCT03467620 WITHDRAWN
Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease
University of Illinois at Chicago
NCT03035058 WITHDRAWN
Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease
Takeda
NCT02771457 WITHDRAWN
Managing Infliximab Reinduction After Temporary Discontinuation of Drug
NYU Langone Health

Data: ClinicalTrials.gov